The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 0.14 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M -2.26 — no flag raisedOK
- Earnings quality 74/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as AMGEN INC reports it. History and quarterly detail are in the app.
- Product sales$35.1B
- Other products$7.3B
- Prolia$4.4B
- Repatha$3.0B
- Otezla$2.3B
Leadership changes
From AMGEN INC's own filings, the day they're filed.
- Peter H. Griffith · Chief Financial Officer · departureeff. 2026-08-31
- Thomas Dittrich · Chief Financial Officer · departureeff. 2026-07-01
- Peter H. Griffith · Chief Financial Officer · departureeff. 2026-06-01
Latest filings
- 8-K · Company announcement2026-05-20
- 8-K · Company announcement2026-05-19
- 10-Q · Quarterly report2026-05-01
- 8-K · Company announcement2026-04-30
- 8-K · Company announcement2026-04-22
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about AMGEN INC, every answer cited🔒
- The Intelligence Brief — added when AMGEN INC's brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.